A live and archived webcast of the event can be accessed on the Events and Presentations page on the Investors section of the Aclaris website at http://www.aclaristx.com/events-and-webcasts. A replay of the webcast will be archived on the Aclaris website following the event. If you are a member of the investment community and would like to attend, please RSVP to mtung@aclaristx.com. The agenda will include:
Commercial Update
Brett Fair – Senior Vice President, Commercial OperationsSheila Kennedy – Vice President, MarketingJohn Bagdasarian – Vice President, Professional RelationsErika Dunbar – Director, Marketing
KOL Discussion on Seborrheic Keratosis and Warts
Adam Friedman , MD, FAAD - is an Associate Professor of Dermatology and serves as Residency Program Director, Director ofTranslational Research , and Director of the Supportive Oncodermatology Program in theDepartment of Dermatology at TheGeorge Washington University School of Medicine & Health Sciences .Michael Gold , MD, FAAD - is the founder and medical director ofGold Skin Care Center ,Advanced Aesthetics Medical Spa , The Laser & Rejuvenation Center, andTennessee Clinical Research Center inNashville, TN.
Genetics and Immunology of Alopecia Areata
Angela M. Christiano , Ph.D., FACMG - is the Richard and Mildred Rhodebeck Professor of Dermatology and Professor of Genetics and Development atColumbia University Medical Center (CUMC). She is also the Director of Research in theDepartment of Dermatology at CUMC.
Immuno-Dermatology Pipeline Review (Former Confluence Team)
Walter Smith - has over 35 years of experience in leading pharmaceutical research and development. Formerly the Vice President and Global Head of Pfizer Inflammation/Immunology Research Therapeutic Areas, Mr. Smith had portfolio responsibility from discovery through commercialization.Joe Monahan , Ph.D. - has over 30 years of biochemical pharmacology and drug discovery experience. Formerly an Executive Director in the Pfizer Inflammation Research Unit, Dr. Monahan directed numerous drug discovery programs into Phase 1 and 2 stages of clinical development, and while at Pfizer he led the global kinase technology platform.Jon Jacobsen , Ph.D. - has over 30 years of medicinal chemistry and drug discovery experience. Formerly a senior scientist and Director in thePfizer Chemistry Department , he has directed chemistry and project teams to provide Phase 1 candidates and has also served on discovery teams for compounds in Phase 1 and 2 stages of development.Paul Changelian , Ph.D. - has over 25 years of experience in drug discovery. His work focused on several areas, including renal transplantation, autoimmune disease, mitochondrial metabolism and oncology. He identified the JAK kinases as potential drug targets and during his 18 years at Pfizer, his laboratory was responsible for the preclinical candidate delivery and development of tofacitinib in rheumatoid arthritis, psoriasis, IBD and renal transplant.
About
Aclaris Contact
Investor Relations
484-329-2140
mtung@aclaristx.com
Media Contact
TogoRun
917-242-1087
M.Caprino@togorun.com
Source: Aclaris Therapeutics, Inc.